SCHEMBL396457

SCHEMBL396457

Cc1cccc(C(=O)Nc2cccc(Oc3ccc4c(c3)NC(=O)C4=Cc3cc(C(=O)O)cn3C(CC(N)=O)N(C)C)c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 3/20 0.38
▸ FGFR1 P11362 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NR1H4 Q96RI1 3/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ NTRK1 P04629 3/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ KIT P10721 1/20 0.36
▸ FLT4 P35916 1/20 0.36
▸ FLT3 P36888 1/20 0.36
▸ NTRK3 Q16288 2/20 0.36
▸ TLK2 Q86UE8 3/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ KCNK3 O14649 1/20 0.35
▸ KCNK9 Q9NPC2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396427 0.91 NTRK1 (0.46) KDRFGFR1NTRK1FLT1KIT
SCHEMBL398657 0.88 NTRK1 (0.37) KDRFGFR1CYP1A2CYP3A4GAA
SCHEMBL396735 0.83 NTRK1 (0.37) KDRFGFR1CYP1A2CYP3A4GAA
SCHEMBL395051 0.78 NTRK1 (0.45) KDRFGFR1KMT2ANTRK1FLT1
SCHEMBL398703 0.77 KDR (0.53) KDRFGFR1CYP1A2CYP3A4GAA
SCHEMBL398702 0.77 KDR (0.53) KDRFGFR1CYP1A2CYP3A4GAA
SCHEMBL399189 0.76 NTRK1 (0.46) KDRFGFR1NTRK1FLT1KIT
SCHEMBL395647 0.74 FLT3 (0.62) KDRNTRK1KITFLT4FLT3
SCHEMBL395648 0.74 FLT3 (0.62) KDRNTRK1KITFLT4FLT3
SCHEMBL394066 0.72 AKT2 (0.46) KDRCYP1A2CYP3A4GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback